| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| de Verneuil Vanina | EVP and General Counsel | C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO | /s/ Vanina de Verneuil | 04 Nov 2025 | 0002036234 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VIR | Common Stock | Sale | $8,003 | -1,365 | -1.7% | $5.86 | 80,595 | 03 Nov 2025 | Direct | F1, F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
| F2 | Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program. |